The Column Group
The Column Group

The Column Group

A science-driven venture capital firm building early-stage biotechnology companies focused on drug discovery.

Website
2007VC43 portfolio$4.0B AUMSan Francisco, United States

About

The Column Group (TCG) is a venture capital firm dedicated to creating the next generation of biotechnology companies. TCG focuses on early-stage drug discovery, investing in disease-focused companies with the potential to become leaders in their respective fields. The firm employs an edge-to-edge investment model, supporting companies from inception through exit, and emphasizes a hands-on approach to company building.

Key facts

At-a-glance profile data

Website
thecolumngroup.com
Type
VC
Headquarters
San Francisco, United States
Funds raised
$4.0B
Portfolio companies
43
Stages
Seed
Early Stage Venture
Later Stage Venture
Post-IPO
Early Stage
Sector focus
Life Sciences
Healthcare
Biotechnology
Drug Discovery
Oncology

Recent investments

Recent funding rounds The Column Group took part in
DateCompanyRoundAmount
12 Aug 2026InduProSeries B$77M
21 Apr 2026Tortugas NeuroscienceSeries A$106M
1 Jun 2025Tortugas NeuroscienceSeed$29M
3 Mar 2025Tenaya TherapeuticsPublic Offering$53M
1 Oct 2024Tortugas NeuroscienceSeed$29M
21 Sept 2021Hexagon BioSeries B$75M
1 Mar 2021Tenaya TherapeuticsSeries C$106M
18 Jun 2019Hexagon BioSeed$25M
Add first review

Frequently asked

What companies has The Column Group invested in?

The Column Group has invested in InduPro, Tortugas Neuroscience, Tenaya Therapeutics, Hexagon Bio, Genentech (Roche) and 38 more.

Founders (1)
PS
Peter Svennilson
Founder / Managing Partner

Find a founder email